These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 30666091)

  • 1. Hyperprogression after anti-programmed cell death ligand-1 therapy in a patient with recurrent metastatic urothelial bladder carcinoma following first-line cisplatin-based chemotherapy: a case report.
    Mao S; Zhang J; Guo Y; Zhang Z; Wu Y; Zhang W; Wang L; Geng J; Yan Y; Yao X
    Drug Des Devel Ther; 2019; 13():291-300. PubMed ID: 30666091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays.
    Schwamborn K; Ammann JU; Knüchel R; Hartmann A; Baretton G; Lasitschka F; Schirmacher P; Braunschweig T; Tauber R; Erlmeier F; Hieke-Schulz S; Weichert W
    Virchows Arch; 2019 Nov; 475(5):599-608. PubMed ID: 31267201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-Programmed Cell Death 1/Ligand 1 (PD-1/PD-L1) Antibodies for the Treatment of Urothelial Carcinoma: State of the Art and Future Development.
    Powles T; Necchi A; Rosen G; Hariharan S; Apolo AB
    Clin Genitourin Cancer; 2018 Apr; 16(2):117-129. PubMed ID: 29325739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications.
    Wankowicz SAM; Werner L; Orsola A; Novak J; Bowden M; Choueiri TK; de Torres I; Morote J; Freeman GJ; Signoretti S; Bellmunt J
    J Urol; 2017 Oct; 198(4):817-823. PubMed ID: 28487100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer.
    Massard C; Gordon MS; Sharma S; Rafii S; Wainberg ZA; Luke J; Curiel TJ; Colon-Otero G; Hamid O; Sanborn RE; O'Donnell PH; Drakaki A; Tan W; Kurland JF; Rebelatto MC; Jin X; Blake-Haskins JA; Gupta A; Segal NH
    J Clin Oncol; 2016 Sep; 34(26):3119-25. PubMed ID: 27269937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of programmed cell death ligand-1 expression in patients with bladder urothelial carcinoma undergoing radical cystectomy: A meta-analysis.
    Zhang J; Song L; Zhu H; Liu Q; Wang D
    Front Immunol; 2022; 13():986911. PubMed ID: 36248912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.
    Rosenberg JE; Hoffman-Censits J; Powles T; van der Heijden MS; Balar AV; Necchi A; Dawson N; O'Donnell PH; Balmanoukian A; Loriot Y; Srinivas S; Retz MM; Grivas P; Joseph RW; Galsky MD; Fleming MT; Petrylak DP; Perez-Gracia JL; Burris HA; Castellano D; Canil C; Bellmunt J; Bajorin D; Nickles D; Bourgon R; Frampton GM; Cui N; Mariathasan S; Abidoye O; Fine GD; Dreicer R
    Lancet; 2016 May; 387(10031):1909-20. PubMed ID: 26952546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [First-line treatment of metastatic urothelial carcinoma : Update immuno-oncology].
    Zacharis A; Grüllich C
    Urologe A; 2020 Jul; 59(7):797-803. PubMed ID: 32500171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-L1 expression in urothelial bladder cancer varies more among specimen types than between companion assays.
    de Jong JJ; Stoop H; Boormans JL; van Leenders GJLH
    Virchows Arch; 2021 Oct; 479(4):705-713. PubMed ID: 33909149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer.
    Powles T; Eder JP; Fine GD; Braiteh FS; Loriot Y; Cruz C; Bellmunt J; Burris HA; Petrylak DP; Teng SL; Shen X; Boyd Z; Hegde PS; Chen DS; Vogelzang NJ
    Nature; 2014 Nov; 515(7528):558-62. PubMed ID: 25428503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions.
    Tripathi A; Plimack ER
    Curr Urol Rep; 2018 Nov; 19(12):109. PubMed ID: 30406502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment Approaches for Cisplatin-Ineligible Patients with Invasive Bladder Cancer.
    Einstein DJ; Sonpavde G
    Curr Treat Options Oncol; 2019 Feb; 20(2):12. PubMed ID: 30741358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperprogression after anti-programmed death-1 therapy in a patient with urothelial bladder carcinoma: A case report.
    Yang HY; Du YX; Hou YJ; Lu DR; Xue P
    World J Clin Cases; 2023 Oct; 11(28):6841-6849. PubMed ID: 37901032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Supplementary granulocyte macrophage colony-stimulating factor to chemotherapy and programmed death-ligand 1 blockade decreases local recurrence after surgery in bladder cancer.
    Miyake M; Hori S; Ohnishi S; Toritsuka M; Fujii T; Shimizu T; Owari T; Morizawa Y; Gotoh D; Itami Y; Nakai Y; Anai S; Torimoto K; Tanaka N; Fujimoto K
    Cancer Sci; 2019 Oct; 110(10):3315-3327. PubMed ID: 31385407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Programmed death ligand-1 is associated with tumor infiltrating lymphocytes and poorer survival in urothelial cell carcinoma of the bladder.
    Wang B; Pan W; Yang M; Yang W; He W; Chen X; Bi J; Jiang N; Huang J; Lin T
    Cancer Sci; 2019 Feb; 110(2):489-498. PubMed ID: 30548363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Focus on Biochemical and Clinical Predictors of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma: Where Do We Stand?
    Roviello G; Catalano M; Nobili S; Santi R; Mini E; Nesi G
    Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33114616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Checkpoint inhibitors: the new treatment paradigm for urothelial bladder cancer.
    Katz H; Wassie E; Alsharedi M
    Med Oncol; 2017 Sep; 34(10):170. PubMed ID: 28864844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic Sequencing for Bladder Urothelial Carcinoma and Its Clinical Implications for Immunotherapy.
    Kim R; Hong JY; Lee J; Kwon GY; Jeong BC; Park SH
    Cancer Res Treat; 2022 Jul; 54(3):894-906. PubMed ID: 34793662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of immunotherapy in bladder cancer.
    Rhea LP; Mendez-Marti S; Kim D; Aragon-Ching JB
    Cancer Treat Res Commun; 2021; 26():100296. PubMed ID: 33421822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen receptor and immune cell PD-L1 expression in bladder tumors predicts disease recurrence and survival.
    Toren P; Brisson H; Simonyan D; Hovington H; Lacombe L; Bergeron A; Fradet Y
    World J Urol; 2021 May; 39(5):1549-1558. PubMed ID: 32676741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.